Literature DB >> 33496196

Development and evaluation of a heparin gel for transdermal delivery via laser-generated micropores.

Deepal Vora1, Yujin Kim1, Ajay K Banga1.   

Abstract

Aim: Our study investigated the feasibility of transdermal delivery of heparin, an anticoagulant used against venous thromboembolism, as an alternative to intravenous administration. Materials & methods: Skin was pretreated using ablative laser (Precise Laser Epidermal System [P.L.E.A.S.E.®] technology) for enhanced delivery of heparin. In vitro permeation studies using static Franz diffusion cells provided a comparison between delivery from 0.3% w/v heparin-loaded poloxamer gel and solution across untreated and laser-treated dermatomed porcine ear skin. 
Results: No passive delivery of heparin was observed. Laser-assisted delivery from solution (26.07 ± 1.82 μg/cm2) was higher (p < 0.05) than delivery from heparin gel (11.28 ± 5.32 μg/cm2). However, gel is likely to sustain the delivery over prolonged periods like a maintenance dose via continuous intravenous infusion.
Conclusion: Thus, ablative laser pretreatment successfully delivered heparin, establishing the feasibility of delivering hydrophilic macromolecules using the transdermal route.

Entities:  

Keywords:  ablative laser; heparin; macromolecule; microporation; poloxamer gel; skin permeation; transdermal delivery

Year:  2021        PMID: 33496196     DOI: 10.4155/tde-2020-0024

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  3 in total

1.  Microneedle Mediated Iontophoretic Delivery of Tofacitinib Citrate.

Authors:  Amruta A Dandekar; Harsha T Garimella; Carrie L German; Ajay K Banga
Journal:  Pharm Res       Date:  2022-02-16       Impact factor: 4.580

2.  Microneedle and iontophoresis mediated delivery of methotrexate into and across healthy and psoriatic skin.

Authors:  Deepal Vora; Harsha T Garimella; Carrie L German; Ajay K Banga
Journal:  Int J Pharm       Date:  2022-03-21       Impact factor: 6.510

3.  Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer.

Authors:  Deepal Vora; Amruta Dandekar; Sonalika Bhattaccharjee; Onkar N Singh; Vivek Agrahari; M Melissa Peet; Gustavo F Doncel; Ajay K Banga
Journal:  Pharmaceutics       Date:  2022-03-20       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.